Monday, November 30, 2020
The awarding of grants paves the way for the next seven years of science-based clinical HIV research.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced the clinical researchers and institutions that will lead four NIH clinical trial networks in HIV during over the next seven years to conduct the innovative and effective clinical research needed to accelerate progress against the HIV pandemic. NIAID has also awarded grants to 35 US and international institutions selected as HIV Clinical Trial Units (CTUs). NIAID and co-funded NIH institutes plan to provide approximately $ 375.3 million in the first year to support the networks.
“Achieving a sustainable end to the HIV pandemic will require the continued development of new HIV prevention and treatment strategies, as well as the optimal implementation of existing tools,” said Anthony S. Fauci, Director of NIAID, “La The new network structure will increase the efficiency and effectiveness of NIH HIV clinical trial operations to quickly answer critical research questions that will move us closer to this goal, while still ensuring the safety of clinical trial participants.
The process of refining the NIH HIV Clinical Trials Networks began in 2017 and involved extensive consultations with researchers, clinicians, advocates, people living with or at risk for HIV and others. stakeholders. The new, streamlined network structure will reduce administrative and surveillance costs, allowing more funds to be allocated to clinical trials to advance four key areas of research: HIV prevention; HIV vaccines; therapy for HIV / AIDS in adults; and maternal, adolescent and pediatric HIV / AIDS therapy. Networks also have the opportunity to leverage their infrastructure to respond quickly to emerging infectious diseases, such as coronavirus disease 2019 (COVID-19).
The new structure includes a network that will focus on the development of a safe, effective and sustainable preventive HIV vaccine, and one that will work to advance a range of non-vaccine HIV prevention products and strategies to meet the needs of HIV. needs and preferences of diverse populations around the world. . Two therapeutic networks will develop and evaluate potential new treatments and cure strategies for HIV and HIV-related complications and co-infections. One of these networks will focus on adults, while the other will focus on infants, children, adolescents, and pregnant and postpartum women. HIV prevention and vaccine research for maternal, pediatric and adolescent populations will be carried out by the HIV prevention and vaccine networks, with the help of the therapeutic network focused on these populations.
The four networks will lead, coordinate and conduct NIH-funded clinical research around the world in close collaboration with each other, NIAID, other NIH partner institutes and centers, industry and non-research organizations. government. Each network is headed by a Leadership and Operations Center (LOC) and includes a Laboratory Center (LC) and a Statistics and Data Management Center (SDMC). The principal investigators, institutions and grant numbers of these awards are as follows:
HIV Vaccine Trials Network (HVTN)
LOC: Lawrence Corey, Dan H. Barouch, Glenda E. Gray, Georgia D. Tomaras; Fred Hutchinson Cancer Research Center, Seattle; 2 UM1 AI068614-15
CL: Margaret J. McElrath; Fred Hutchinson Cancer Research Center, Seattle; 2 UM1 AI068618-15
SDMC: Peter B. Gilbert, Yunda Huang, Holly Janes; Fred Hutchinson Cancer Research Center, Seattle; 2 UM1 AI068635-15
HIV Prevention Trials Network (HPTN)
LOC: Myron S. Cohen, Wafaa M. El-Sadr; Family Health International, Durham, North Carolina; 2 UM1 AI068619-15
CL: Susan H. Eshleman; Johns Hopkins University, Baltimore; 2 UM1 AI068613-15
SDMC: Deborah J. Donnell; Fred Hutchinson Cancer Research Center, Seattle; 2 UM1 AI068617-15
AIDS Clinical Trials Group (ACTG)
LOC: Judith S. Currier, Joseph J. Eron; University of California at Los Angeles; 2 UM1 AI068636-15
CL: Thanks M. Aldrovandi; University of California at Los Angeles; 2 UM1 AI106701-08
SDMC: Michael D. Hughes, Marlene Cooper; Harvard School of Public Health, Boston; 2 UM1 AI068634-15
International Maternal and Adolescent AIDS Clinical Trials Network (IMPAACT)
LOC: Sharon A. Nachman; Johns Hopkins University, Baltimore; 2 UM1 AI068632-15
CL: Thanks M. Aldrovandi; University of California at Los Angeles; 2 UM1 AI106716-09
SDMC: David E. Shapiro, Marlene Cooper; Harvard School of Public Health, Boston; 2 UM1 AI068616-15
The 35 CTUs will provide scientific and administrative expertise, as well as the infrastructure to conduct clinical trials within the networks. A complete list of UTCs, including principal investigators and their affiliations, is available online. Each CTU supports up to eight clinical research sites. Collectively, CTUs support 101 clinical research sites in 18 countries in North America, South America, Africa and Asia. This includes 45 sites in the United States. See a map showing the locations of clinical research sites.
Other NIH institutes that will collaborate with one or more HIV clinical trials networks include the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); the National Institute for Dental and Craniofacial Research (NIDCR); the National Institute for the Fight against Drug Abuse (NIDA); National Institute of Mental Health (NIMH); and the National Institute of Neurological Disorders and Stroke (NINDS).
To learn more about these new awards and the process of refining the NIH HIV Clinical Trials Networks, see the NIAID Refine the HIV clinical trial business website.
NIAID conducts and supports research – at the NIH, in the United States, and around the world – to study the causes of infectious and immune diseases and to develop better ways to prevent, diagnose, and treat these diseases. Press releases, fact sheets and other materials related to NIAID are available on the site NIAID website.
About the National Institutes of Health (NIH):The NIH, the national agency for medical research, comprises 27 institutes and centers and is part of the US Department of Health and Human Services. The NIH is the principal federal agency that conducts and supports basic, clinical, and translational medical research, and studies the causes, treatments, and cures for common and rare diseases. For more information about the NIH and its programs, visit www.nih.gov.
NIH… Transforming Discovery into Health®